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Abstract
Background
Kidney dysfunction is prevalent and impacts prognosis in patients with acute decompen-
sated heart failure (ADHF). However, most previous reports were from a single hospital, lim-
iting their generalizability. Also, contemporary data using new equation for estimated
glomerular filtration rate (eGFR) are needed.
Methods and results
We analyzed data from the ARIC Community Surveillance for ADHF conducted for resi-
dents aged55 years in four US communities between 2005–2011. All ADHF cases (n = 5,
391) were adjudicated and weighted to represent those communities (24,932 weighted
cases). The association of kidney function (creatinine-based eGFR by the CKD-EPI equa-
tion and blood urea nitrogen [BUN]) during hospitalization with 1-year mortality was
assessed using logistic regression. Based on worst and last serum creatinine, there were
82.5% and 70.6% with reduced eGFR (<60 ml/min/1.73m2) and 37.4% and 26.6% with
severely reduced eGFR (<30 ml/min/1.73m2), respectively. Lower eGFR (regardless of last
or worst eGFR), particularly eGFR <30 ml/min/1.73m2, was significantly associated with
higher 1-year mortality independently of potential confounders (odds ratio 1.60 [95% CI
1.26–2.04] for last eGFR 15–29 ml/min/1.73m2 and 2.30 [1.76–3.00] for <15 compared to
eGFR60). The association was largely consistent across demographic subgroups. Of
interest, when both eGFR and BUN were modeled together, only BUN remained significant.
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Conclusions
Severely reduced eGFR (<30 ml/min/1.73m2) was observed in ~30% of ADHF cases and
was an independent predictor of 1-year mortality in community. For prediction, BUN
appeared to be superior to eGFR. These findings suggest the need of close attention to kid-
ney dysfunction among ADHF patients.
Introduction
Reduced kidney function is a strong predictor of adverse health outcomes in a broad range of
populations [1–6]. Patients with heart failure (HF) are no exception, and various studies have
reported that low kidney function is associated with poor prognosis in this population as well
[7–21]. However, many of these studies investigate patients with compensated chronic HF [7–
15] and data on patients with acute decompensated HF (ADHF) are relatively limited [16–21].
More importantly, those studies with ADHF patients are from a clinical trial with stringent
inclusion criteria [16] or from a single hospital [17–19]. Thus, the prevalence of kidney dys-
function and its prognostic impact among ADHF patients in the community are yet to be
investigated. Though a report from a large registry study in the US [20, 21] may more reflect
community setting than trials or single center studies, data completeness and lack of validation
of ADHF cases remain important challenges [22]. Furthermore, many of above studies
explored serum creatinine levels or creatinine clearance but not necessarily the best overall
measure of kidney function recommended in clinical guidelines, estimated glomerular filtra-
tion rate (eGFR) [23]. Also, contemporary data are warranted since new and more valid equa-
tions for estimating GFR are currently available [24, 25].
In above contexts, the aims of this study were to evaluate the prevalence of reduced eGFR
assessed by the contemporary creatinine-based CKD-EPI equation [25, 26] and its prognostic
impact among patients hospitalized for acute decompensated HF (ADHF) in community hos-
pitals using the community surveillance data from the Atherosclerosis Risk in Communities
(ARIC) [27]. We also evaluated whether the impact of kidney dysfunction was consistent
across subgroups according to age, sex, and race and contrasted the prognostic impact of
eGFR and blood urea nitrogen (BUN), another parameter of kidney function demonstrating
strong prognostic value in patients with ADHF [20, 21].
Methods
Study design and population
Details of the ARIC Community Surveillance Study have been provided elsewhere [27, 28].
Briefly, beginning in 2005, the ARIC Study performed continuous community surveillance of
hospitalized ADHF for all residents aged55 years in four US communities: Forsyth County,
North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County,
Maryland. A stratified random sample of eligible hospitalizations for HF was selected accord-
ing to the following International Classification of Diseases, 9th Revision, Clinical Modifica-
tion (ICD-9-CM) discharge diagnosis codes in any position: rheumatic heart disease (398.91),
hypertensive heart disease with HF (402.01, 402.11, 402.91), hypertensive heart disease and
renal failure with congestive HF (404.01, 404.03, 404.11, 404.13, 404.91, 404.93), cor pulmonale
(415.0), unspecified chronic pulmonary heart disease (416.9), other primary cardiomyopathies
(425.4), HF (428.x), unspecified acute edema of lung (518.4), and dyspnea and respiratory
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abnormalities (786.0x). The sampling probabilities varied by ICD-9-CM codes (428 and non-
428), field center, gender, and race to optimize variance estimates across these groups.
Hospital records of eligible HF cases were abstracted by trained abstractors if there is any
evidence of decompensation or new onset of HF symptoms or any mention by a physician
that HF was the reason for hospitalization in the medical record. Fully abstracted cases were
classified by computer algorithm or two physicians of the ARIC Mortality and Morbidity Clas-
sification Committee as definite ADHF, possible ADHF, chronic stable HF, HF unlikely, or
unclassifiable based on symptoms, signs from physical examination, laboratory, and imaging,
and HF-specific treatment. None of authors had direct access to information that could iden-
tify individuals. Disagreements were adjudicated by the Committee chair. For this study, defi-
nite and possible cases were considered as ADHF. Between 2005 and 2011, 5,946 ADHF cases
were identified out of 15,660 eligible cases. Of these, we excluded cases other than black or
white or with missing variables of interest (n = 555), leaving the study sample of 5,391
unweighted cases corresponding to 24,932 cases in those four communities.
Exposures and covariates
All data on exposures and covariates were obtained from detailed abstraction of the medical
record. For laboratory measurements, ARIC systematically recorded their worst (e.g., highest
value for serum creatinine and BUN and lowest value for hemoglobin and sodium) and last
values during hospitalization. As recommended in clinical guidelines [23], kidney function
was primarily evaluated by eGFR, which was calculated using CKD-EPI equation with the
worst and last serum creatinine, respectively [25, 26]. We also analyzed BUN, as an alternative
kidney dysfunction marker, since its prognostic value has been demonstrated in patients with
ADHF [20, 21]. Covariates of interest were age, race, gender, current smoking status, health
insurance type (Medicare/Medicaid, private, or others), diabetes, hypertension, history of cor-
onary heart disease, HF type (preserved vs. reduced ejection fraction [< vs.50%]), history of
chronic obstructive pulmonary disease, hemoglobin, and serum sodium.
Mortality outcomes
Mortality status over 1 year after ADHF admission was identified through the linkage to the
National Death Index. Although the primary outcome was 1-year mortality, we also assessed
in-hospital mortality and 28-day mortality.
Statistical analysis
All analyses were weighted by sampling fractions specific to each of the ARIC communities,
accounting for population size, sex, and race. Baseline characteristics were compared across
clinical eGFR categories,60, 45–59, 30–44, 30–15, and<15 ml/min/1.73m2 or on dialysis
[23]. Cumulative survival in every eGFR category was illustrated using Kaplan-Meier esti-
mates. Since two of three follow-up periods in this study were short, we used logistic regression
models to quantify the association of kidney function with mortality after accounting for the
covariates listed above. We separately adjusted for hemoglobin and sodium, since they can be
mediators linking reduced kidney function to poor prognosis. We also tested separate models
simultaneously incorporating both kidney parameters of interest, eGFR and BUN. For a fair
comparison, BUN was categorized into five groups corresponding to the percentiles based on
clinical eGFR categories shown above. As both worst and last eGFR have respective aspects
potentially leading to poorer outcomes than the other (i.e., worst may account for deteriora-
tion during hospitalization such as acute kidney injury, and last may reflect conditions
Kidney dysfunction in ADHF
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chronologically closest to outcomes), we basically analyzed them in parallel. We repeated our
analysis in demographic subgroups and tested interaction based on likelihood ratio test.
We also assessed whether evidence-based HF treatment such as beta-blockers, renin-angio-
tensin system inhibitors, and diuretics was provided at discharge differently across eGFR cate-
gories [29] and, if so, whether treatment status modified the association of kidney function
with mortality. For this specific part of analysis, as the length of stay may reflect disease severity
and thus may influence indication of HF-specific medications, we restricted to cases that were
discharged alive within 28 days. Given that the medications were assessed at discharge, we
focused on last eGFR for this analysis. All statistical analyses were conducted with SAS (SAS
Institute Inc. Cary, North Carolina).
Results
Of the weighted 24,932 ADHF cases, there were 70.6% and 82.5% cases with reduced eGFR
(<60 ml/min/1.73m2) based on last and worst serum creatinine, and 26.6% and 37.4% with
severely reduced eGFR (<30 ml/min/1.73m2), respectively (Table 1 and S1 Table). Those with
reduced eGFR were more likely to be women, white, and older and to have hypertension, dia-
betes, and coronary heart disease compared to those with preserved eGFR. In contrast, those
with reduced eGFR were unlikely to be current smoker and have history of chronic obstructive
pulmonary disease.
Regardless of whether we used worst or last serum creatinine, patients with severely
reduced eGFR <30 ml/min/1.73m2 demonstrated evidently poor prognosis, with 1 year
Table 1. Baseline characteristics according to eGFR categories based on the last serum creatinine levels during ADHF hospitalization.
Baseline characteristics eGFR:60+ eGFR:60–45 eGFR:45–30 eGFR:30–15 eGFR<15
Weighted N 7329 (29.4) 5295 (21.2) 5679 (22.8) 3934 (15.8) 2696 (10.8)
Age 72 (22.5) 76 (22.7) 78 (22.1) 79 (20.2) 73 (21.1)
Female 3526 (48.1) 2848 (53.8) 3278 (57.7) 2154 (54.8) 1357 (50.3)
African-Americans 2404 (32.8) 1342 (25.3) 1380 (24.3) 1032 (26.2) 1112 (41.2)
Smoker 1439 (19.6) 711 (13.4) 544 (9.6) 332 (8.4) 331 (12.3)
Hypertension 5943 (81.1) 4422 (83.5) 4892 (86.1) 3379 (85.9) 2427 (90.0)
Diabetes 3196 (43.6) 2209 (41.7) 2621 (46.2) 2207 (56.1) 1694 (62.8)
Health Insurance
Medicare/Medicaid 1997 (29.0) 1482 (29.2) 1614 (29.2) 1093 (28.7) 1043 (40.1)
Private 4887 (71.0) 3591 (70.8) 3921 (70.8) 2710 (71.3) 1559 (59.9)
History of HF 4634 (63.2) 3759 (71.0) 4214 (74.2) 2983 (75.8) 2082 (77.2)
Prior HF hospitalization 2300 (31.4) 1750 (33.1) 2198 (38.7) 1459 (37.1) 1162 (43.1)
Prior HF treat 3760 (51.3) 3216 (60.7) 3611 (63.6) 2542 (64.6) 1727 (64.1)
Ejection fraction
Preserved 2936 (44.0) 2052 (42.5) 2362 (45.2) 1482 (42.7) 1040 (45.5)
Reduced 3737 (56.0) 2773 (57.5) 2859 (54.8) 1987 (57.3) 1244 (54.5)
COPD 2870 (39.2) 1942 (36.7) 1975 (34.8) 1213 (30.8) 851 (31.6)
Coronary Disease 3145 (42.9) 2421 (45.7) 2785 (49.0) 1896 (48.2) 1257 (46.6)
Hemoglobin 12 (1.9) 12 (1.9) 11 (1.8) 11 (1.5) 11 (1.7)
Sodium 139 (3.9) 139 (3.6) 139 (3.9) 139 (4.5) 138 (4.5)
BUN 20 (9.6) 26 (11.3) 35 (15.7) 52 (21.1) 52 (28.9)
Systolic BP 142 (31.4) 142 (33.2) 142 (33.2) 140 (34.4) 145 (37.9)
Diastolic BP 79 (20.0) 78 (19.6) 76 (20.0) 75 (20.0) 77 (20.8)
Values are mean (SD) and n (%)
https://doi.org/10.1371/journal.pone.0181373.t001
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survival close to 50% (Fig 1). eGFR60 ml/min/1.73m2 consistently demonstrated most
favorable 1-year prognosis, but its separation with eGFR categories 45–59 (CKD stage 3a) was
not evident with last eGFR (Fig 1B). The associations of eGFR <30 ml/min/1.73m2 with poor
prognosis were significant even after accounting for key potential confounders for both worst
and last eGFRs (Table 2). The effect size tended to be larger for short-term mortality (i.e., in-
hospital and 28-day) compared to 1-year mortality. The results were overall comparable
between worst and last eGFRs, although eGFR 30–44 ml/min/1.73m2 reached significance
only with last eGFR for 1-year mortality. The association was qualitatively consistent across
demographic subgroups, without any significant interactions (Fig 2).
Further adjustment for prespecified potential mediators, i.e., hemoglobin and sodium, did
not alter the association between reduced kidney function and mortality (Table 3). On the
other hand, when BUN was included in the model, eGFR was no longer significantly associ-
ated with increased mortality (Table 3). In contrast, BUN, regardless of its worst (highest) or
last value, was significantly associated with 1-year mortality even after accounting for eGFR as
well as other potential confounders (Table 4).
Finally, we evaluated whether the use of evidence-based HF medications at discharge
varies across last eGFR categories among those who were discharged alive within 28 days
(unweighted n = 4,765 corresponding to weighted 21,941cases) (Table 5). Patients with
reduced eGFR were less likely to receive renin-angiotensin system inhibitors. The use of beta-
blockers and diuretics were largely comparable across eGFR categories except for diuretics in
patients with kidney failure (eGFR <15 ml/min/1.73m2). However, the association of low
eGFR with mortality risk was consistent even after additionally adjusting for or stratified by
the use of HF medications (data not shown).
Discussion
In this study based on the ARIC Community Surveillance, we confirmed that reduced eGFR is
prevalent (~70% with last eGFR <60 ml/min/1.73m2 and ~30% with last eGFR<30 ml/min/
1.73m2) in ADHF patients and confers mortality risk, particularly below eGFR<30 ml/min/
1.73m2. This association remained significant after adjustment for potential confounders (e.g.,
diabetes and hypertension) and mediators (hemoglobin and sodium). Its contribution to poor
prognosis tended to be more evident for shorter term (in-hospital or 28-day mortality) than
1-year outcome. Although as previously reported we confirmed that some evidence-based HF
medications were less likely to be used among those with reduced eGFR, the relationship
between low eGFR and mortality was not necessarily altered even when we accounted for
these medications. As previously reported [30], of note, BUN, another kidney function marker,
demonstrated a stronger association with poor prognosis compared to eGFR in ADHF
patients.
The prevalence of reduced eGFR including severe stages among ADHF patients was higher
in our study than in previous studies using eGFR or creatinine clearance as a marker of kidney
function (~75% vs. 26%-64% for eGFR or creatinine clearance <60 and ~30% vs.<20% for
eGFR<30 ml/min/1.73m2) [7, 10, 20]. There seem to be a few potential reasons behind this
observation. Some of the previous studies were clinical trials and excluded those with reduced
eGFR (or elevated serum creatinine) [7, 10]. Also, those studies included HF patients con-
trolled in outpatient settings. In this context, it is important that our estimates were even
higher than that from a large registry study of HF hospitalizations, ADHERE (64% with eGFR
<60 ml/min/1.73m2 and 8% with <30 ml/min/1.73m2) [20]. ADHERE used serum creatinine
at admission of ADHF, and it is possible that their serum creatinine concentrations were
diluted as a result of fluid congestion in this population. Also, this registry relied on ICD codes
Kidney dysfunction in ADHF
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for identifying HF and thus might include some stable chronic HF cases. Moreover, ADHERE
obtained data between 2001 and 2004 whereas our study are more contemporary (2005
through 2011), and the prevalence of CKD in the community is estimated to be rising [31].
As previously reported [30], we confirmed that BUN is a stronger predictor of mortality
than creatinine-based eGFR in ADHF patients. Actually, a recent systematic review reveals
that BUN is one of the strongest predictors of poor prognosis in this clinical population [32].
BUN is a well-known marker of kidney function, but recent investigations highlight that BUN
also reflects activation of neurohumoral axis, an important pathophysiological pathway in
ADHF [33]. Also, BUN is known to reflect decreased kidney perfusion and thus may indicate
cardiac low output or the need of extensive diuresis. Nevertheless, in terms of risk prediction
among ADHF patients, taken previous and our results together, it seems reasonable to priori-
tize BUN over creatinine-based eGFR. However, eGFR should still be the first choice for
assessing kidney function itself, as recommended in clinical guidelines, for drug dose adjust-
ment and kidney function monitoring over the clinical course [23].
Given that reduced eGFR is consistently associated with high mortality in various populations
[1–6], it is not surprising that reduced eGFR confers mortality risk in ADHF patients as well.
Potential mechanisms linking kidney dysfunction to mortality risk include volume overload, oxi-
dative stress, inflammation, and uremic toxins [34]. Also, poor control of traditional risk factors
such as hypertension in patients with kidney disease is considered as an important contributor
[34]. It has been demonstrated that patients with CKD are less likely to receive evidence-based
therapy for cardiovascular disease management [29], and we confirmed this pattern for renin-
angiotensin system inhibitors in our study. However, the relationship between kidney dysfunc-
tion and mortality was consistent even after accounting for the use of HF medications. Neverthe-
less, close attention to the quality of evidence-based HF management is warranted among HF
patients with kidney dysfunction [29]. Also, as aforementioned, clinical trials frequently exclude
patients with reduced kidney function [7, 10] and thus investigations of established HF medica-
tions specifically in HF patients with reduced kidney function would be needed.
Our study has several limitations. First, serum creatinine data at admission were not specifi-
cally abstracted, and thus we could not dissect impact of eGFR at admission and change in
eGFR from admission [18, 35]. However, consistent findings regardless of when worst and last
Fig 1. 1-year survival according to eGFR categories based on the worst (A) and last (B) serum creatinine
after ADHF admission.
https://doi.org/10.1371/journal.pone.0181373.g001
Table 2. Adjusted odds ratio of mortality outcomes according to eGFR categories.
Mortality eGFR categories
60 45–59 30–44 15–29 <15/dialysis
Worst
In-hospital reference 0.96 (0.53, 1.75) 1.11 (0.64, 1.91) 2.04 (1.19, 3.48) 4.79 (2.88, 7.95)
28-day reference 1.14 (0.73, 1.79) 0.99 (0.66, 1.51) 2.09 (1.40, 3.12) 3.42 (2.27, 5.15)
1-year reference 1.05 (0.81, 1.36) 1.26 (0.99, 1.61) 1.96 (1.53, 2.53) 2.58 (1.96, 3.38)
Last
In-hospital reference 0.72 (0.44, 1.18) 1.22 (0.79, 1.90) 2.10 (1.35, 3.26) 4.99 (3.30, 7.56)
28-day reference 0.87 (0.59, 1.27) 1.25 (0.89, 1.77) 2.06 (1.45, 2.92) 3.66 (2.55, 5.25)
1-year reference 0.99 (0.79, 1.24) 1.29 (1.04, 1.60) 1.60 (1.26, 2.04) 2.30 (1.76, 3.00)
Adjusted for primary covariates: age, race, gender, health insurance, diabetes, hypertension, smoke, history of coronary heart disease, heart failure type
(preserved vs. reduced ejection fraction), and chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pone.0181373.t002
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eGFRs were used support robustness of our findings. Second, we did not have information on
whether the measurement of serum creatinine was standardized in relevant hospitals in the
four ARIC communities. Third, we focused on kidney function in this study as we did not
have data on albuminuria, a marker of kidney damage and the other key marker do define and
stage CKD [23]. Thus, studies taking into account albuminuria in ADHF patients are war-
ranted, particularly since close relationship between albuminuria and incident HF has been
reported [36, 37]. Finally, we cannot deny the possibility of residual confounding, as true in
any observation studies.
In conclusion, severely reduced kidney function (eGFR<30 ml/min/1.73m2) is found in
~30% of ADHF patients in the community and confers mortality risk (1 year mortality risk
Fig 2. Adjusted odds ratio of 1-year mortality according to eGFR categories based on last serum creatinine in demographic
subgroups. Models adjusted for primary covariates: age, race, gender, health insurance, diabetes, hypertension, smoke, history of coronary
heart disease, heart failure type (preserved vs. reduced ejection fraction), and chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pone.0181373.g002
Kidney dysfunction in ADHF
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Table 3. Adjusted odds ratio of 1-year mortality according to eGFR categories with additional adjustment for potential mediators (sodium and
hemoglobin) and another kidney measure, blood urea nitrogen (BUN).
eGFR categories
Models including primary covariates plus 60 45–59 30–44 15–29 <15/dialysis
Worst
Hemoglobin reference 1.02 (0.78, 1.33) 1.16 (0.90, 1.48) 1.58 (1.22, 2.05) 2.02 (1.52, 2.68)
Sodium reference 1.07 (0.82, 1.38) 1.28 (1.01, 1.64) 1.92 (1.49, 2.48) 2.40 (1.83, 3.16)
BUN reference 0.93 (0.71, 1.21) 0.94 (0.73, 1.21) 1.06 (0.79, 1.42) 1.04 (0.73, 1.48)
Last
Hemoglobin reference 0.97 (0.78, 1.21) 1.20 (0.96, 1.49) 1.36 (1.06, 1.74) 1.92 (1.46, 2.52)
Sodium reference 1.03 (0.83, 1.29) 1.32 (1.07, 1.64) 1.60 (1.25, 2.04) 2.23 (1.70, 2.91)
BUN reference 0.88 (0.70, 1.10) 0.95 (0.76, 1.19) 0.88 (0.67, 1.14) 1.12 (0.82, 1.53)
Primary covariates included age, race, gender, health insurance, diabetes, hypertension, smoke, history of coronary heart disease, heart failure type
(preserved vs. reduced ejection fraction), and chronic obstructive pulmonary disease.
Hemoglobin, sodium, and BUN were modeled as a continuous variable.
https://doi.org/10.1371/journal.pone.0181373.t003
Table 4. Adjusted odds ratio of mortality outcomes according to BUN categories.
Models BUN categories based on percentiles corresponding to clinical eGFR categories
Worst, range
<21 21–28 29–41 41–64 65
n = 1032 n = 1053 n = 1328 n = 1187 n = 775
In-hospital reference 0.72 (0.35–1.48) 1.74 (0.95–3.18) 3.08 (1.60–5.90) 7.18 (3.54–14.57)
28-day reference 0.79 (0.49–1.28) 1.07 (0.68–1.69) 2.51 (1.53–4.12) 4.73 (2.68–8.34)
1-year reference 1.18 (0.91–1.53) 1.32 (1.01–1.73) 2.12 (1.55–2.88) 4.39 (3.04–6.35)
Last, range
<21 21–28 29–38 39–57 58
n = 1652 n = 1186 n = 985 n = 940 n = 610
In-hospital reference 0.70 (0.40–1.24) 1.34 (0.78–2.31) 3.32 (1.99–5.53) 10.35 (5.85–18.32)
28-day reference 0.81 (0.53–1.23) 1.38 (0.91–2.10) 3.37 (2.21–5.15) 7.90 (4.89–12.78)
1-year reference 1.09 (0.87–1.37) 1.48 (1.16–1.89) 2.25 (1.72–2.93) 5.20 (3.73–7.25)
Adjusted for primary covariates (age, race, gender, health insurance, diabetes, hypertension, smoke, history of coronary heart disease, heart failure type
[preserved vs. reduced ejection fraction], and chronic obstructive pulmonary disease) and eGFR (as a continuous variable).
BUN was divided into five groups to approximately match with percentiles corresponding to clinical categories of eGFR in Table 2. The four cutoff points for
worst and last BUN corresponded to 19th, 39th, 63rd, and 86th percentiles and 31st, 53rd, 71st, and 89th percentiles, respectively, whereas those for clinical
categories of worst and last eGFR in Tables were 19th, 38th, 63rd, and 85th percentiles and 31st, 52nd, 73rd, and 88th percentiles, respectively.
https://doi.org/10.1371/journal.pone.0181373.t004
Table 5. Use of evidence-based HF medications across last eGFR categories among patients who were discharged alive within 28 days.
eGFR categories
Medication 60 45–59 30–44 15–29 <15/dialysis
ACE inhibitors 3484 (52.2) 2422 (48.3) 2090 (40.2) 826 (24.1) 712 (31.7)
ARB 844 (12.7) 685 (13.7) 667 (12.8) 360 (10.5) 210 (9.4)
BETA blocker 4764 (71.4) 3611 (72.0) 3896 (74.9) 2649 (77.4) 1761 (78.4)
Diuretics 5205 (78.0) 4261 (84.9) 4315 (82.9) 2641 (77.1) 1037 (46.2)
Values are N (% in each eGFR category)
https://doi.org/10.1371/journal.pone.0181373.t005
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greater than 40% vs. ~25% if eGFR60 ml/min/1.73m2) beyond potential confounders. In
terms of mortality prediction, another kidney function parameter, BUN, seems superior to
creatinine-based eGFR, probably due to its property reflecting both kidney and non-kidney
pathophysiological pathways. These observations suggest that close attention to ADHF
patients with kidney dysfunction is warranted.
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